Get started
Author

Mirerille Mousseau

Observed names: M MOUSSEAU, M Mousseau, M. Mousseau
Observed institutions: Inserm, Centre Hospitalier Universitaire de Grenoble, Institut Gustave Roussy, Medizinische Hochschule Hannover, Hôpital Louis-Mourier, Centre Hospitalier Universitaire de Besançon, Assistance Publique – Hôpitaux de Paris, Centre Hospitalier Universitaire de Nîmes, Centre Léon Bérard, Institut de Cancérologie de l'Ouest, St Mary's Hospital, Laboratoire Radiopharmaceutiques Biocliniques, Centre Eugène Marquis, CHU Dijon Bourgogne, Centre François Baclesse, Hôpitaux Universitaires Henri-Mondor, Centre Oscar Lambret, Hôtel-Dieu de Paris, Centre Azuréen de Cancérologie, Institut Bergonié, Institut Paoli-Calmettes, Centre Antoine Lacassagne, Institut Jean Godinot, Institut Sainte Catherine, Hôpital Albert Michallon, Institut Strauss, Institut Curie
OpenAlex ID: A5111066022
Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy.
1997 · P Rougier, R Bugat, et al. · Journal of Clinical Oncology · 430
A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1)
2016 · H. Bonnefoi, T. Grellety, et al. · Annals of Oncology · 286
PDF
Intraperitoneal recombinant interferon gamma in ovarian cancer patients with residual disease at second-look laparotomy.
1996 · E Pujade-Lauraine, J P Guastalla, et al. · Journal of Clinical Oncology · 158
A prospective randomized multicentre phase III trial of fotemustine plus whole brain irradiation versus fotemustine alone in cerebral metastases of malignant melanoma
2003 · F Mornex, L Thomas, et al. · Melanoma Research · 154
Impact of primary tumour resection on survival of patients with colorectal cancer and synchronous metastases treated by chemotherapy: Results from the multicenter, randomised trial Fédération Francophone de Cancérologie Digestive 9601
2012 · F. Ferrand, D. Malka, et al. · European Journal of Cancer · 100
PDF
Multicentric evaluation of the MDR phenotype in leukemia
1997 · J-P Marie, S Huet, et al. · Leukemia · 80
First-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer: toxicity and response (PEGASE 02 trial)
1999 · P Viens, T Palangié, et al. · British Journal of Cancer · 62
PDF
Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trials
2018 · Thomas Aparicio, Michel Ducreux, et al. · European Journal of Cancer · 46
PDF
A study of the expression of four chemoresistance-related genes in human primary and metastatic brain tumours
1993 · M. Mousseau, R. Schaerer, et al. · European Journal of Cancer · 44
Efficacy of subsequent therapies in patients with advanced ovarian cancer who relapse after first-line olaparib maintenance: results of the PAOLA-1/ENGOT-ov25 trial
2024 · P. Harter, C. Marth, et al. · Annals of Oncology · 43
PDF
Efficacy and safety of the paclitaxel and carboplatin combination in patients with previously treated advanced ovarian carcinoma
1998 · J.P. Guastalla, E. Pujade-Lauraine, et al. · Annals of Oncology · 41
PDF
Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
2023 · Raphaël Leman, Etienne Muller, et al. · Clinical Cancer Research · 34
PDF
Essai de phase III randomisé comparant la fotémustine seule ou associée à une irradiation encéphalique dans les métastases cérébrales de mélanome†
2003 · F Mornex, L Thomas, et al. · Cancer/Radiothérapie · 34
Randomised Trial Comparing Three Different Schedules of Infusional 5FU and Raltitrexed Alone as First-Line Therapy in Metastatic Colorectal Cancer
2006 · M. Ducreux, O. Bouche, et al. · Oncology · 29
French multicentric evaluation of mdr1 gene expression by RT-PCR in leukemia and solid tumours. Standardization of RT-PCR and preliminary comparisons between RT-PCR and immunohistochemistry in solid tumours
1997 · S Chevillard, Ph Vielh, et al. · Leukemia · 29
Effects of permeability transition inhibition and decrease in cytochrome c content on doxorubicin toxicity in K562 cells
2005 · F De Oliveira, C Chauvin, et al. · Oncogene · 27
Decreased folylpolyglutamate synthetase activity in tumors resistant to fluorouracil-folinic acid treatment: clinical data.
1997 · M Chazal, S Cheradame, et al. · PubMed · 27
A recent increase in the incidence of prostatic carcinoma in a French population: Role of ultrasonography and prostatic specific antigen
1995 · F. Ménégoz, M. Colonna, et al. · European Journal of Cancer · 25
Long-Term Survivor with Intrathecal and Intravenous Trastuzumab Treatment in Metastatic Breast Cancer
2016 · H. Pluchart, E. Jacquet, et al. · Targeted Oncology · 23
Response of chemosensitive and chemoresistant leukemic cell lines to drug therapy: Simultaneous assessment of proliferation, apoptosis, and necrosis
2000 · J. Boutonnat, M. Barbier, et al. · Cytometry · 21
[Hepatic metastasis of unknown primary site].
1991 · M Mousseau, R Schaerer, et al. · PubMed · 21
PKH26 probe in the study of the proliferation of chemoresistant leukemic sublines.
1998 · J Boutonnat, K A Muirhead, et al. · PubMed · 20
Docetaxel combined with irinotecan or 5-fluorouracil in patients with advanced oesophago-gastric cancer: a randomised phase II study
2012 · A Roy, D Cunningham, et al. · British Journal of Cancer · 19
PDF
Optimized fluorescent probe combinations for evaluation of proliferation and necrosis in anthracycline‐treated leukaemic cell lines
1999 · J. Boutonnat, M. Barbier, et al. · Cell Proliferation · 15
PDF
The integration of anthracyclines in the treatment of advanced ovarian cancer
2001 · H.-J. Luck, A. Du Bois, et al. · International Journal of Gynecological Cancer · 14
Works count: 106
Citation count: 1,929
H-index: 21
I10-index: 30
Year
Topic
Type